Analysis of the use of isotretinoin as an adjuvant in rhinoplasty

Int J Dermatol. 2024 Feb;63(2):224-231. doi: 10.1111/ijd.16924. Epub 2023 Nov 28.

Abstract

Background: Isotretinoin has been used in the treatment of acne for decades through the reduction of sebaceous secretion. There are reports in the literature that isotretinoin may be associated with decreased skin thickness, especially in patients with thick nasal skin for whom rhinoplasty can be more challenging. The objective of this study was to quantify, through ultrasonography, the effect of the use of oral isotretinoin in patients undergoing rhinoplasty, pre- and postoperatively.

Methods: Twenty-four patients participated in this randomized, single-blind controlled pilot clinical trial. The intervention group used oral isotretinoin (20 mg/day) for 2 months before rhinoplasty and for 4 months after. Both groups underwent rhinoplasty in the same plastic surgery department and were submitted to high-frequency (22 MHz) ultrasound evaluation of the epidermis and dermis on the nasal dorsum, nasal tip, and left nose wing at the beginning of the study and 6 months after rhinoplasty, with the aim of assessing changes in skin thickness.

Results: Six months after rhinoplasty, a statistically significant reduction was observed in the thickness of the epidermis and dermis of the nasal dorsum and left nose wing, as well as of the epidermis of the nasal tip, but only in the intervention group. The results of the satisfaction questionnaire were better after rhinoplasty in both groups, with no statistical difference between them regarding the specific questions; however, the intervention group had significantly higher satisfaction scores than the control group.

Conclusions: Isotretinoin was effective in reducing the thickness of the skin covering the nose of the evaluated sites.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adjuvants, Immunologic
  • Humans
  • Isotretinoin
  • Nose / surgery
  • Rhinoplasty* / methods
  • Single-Blind Method
  • Treatment Outcome

Substances

  • Isotretinoin
  • Adjuvants, Immunologic